Electroceutical device significantly reduces biofilm burden and rescues tissue from adverse effects of biofilm infection.
Significant new findings on the anti-biofilm efficacy of Vomaris Innovations, Inc.’s Advanced Microcurrent Technology® were featured in a scientific presentation entitled “Electroceutical Principles Disrupt Polymicrobial Bacterial Biofilm in a Porcine Pre-clinical Model”, at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS) Spring conference held April 13 – April 17 in Atlanta, Georgia.
The research, led by Professor Chandan Sen, Ph.D., Professor of Surgery and Director of the Comprehensive Wound Center at OSU Wexner Medical Center, was also selected as a presentation for the Science & Industry awards session in recognition of outstanding scientific merit of the work.
Researchers used porcine full-thickness burns infected with Pseudomonas aeruginosa and Acinetobacter baumannii biofilms, and subsequently spontaneously colonized by other species. Wounds were treated twice weekly for 56 days with either a placebo dressing or the Vomaris wireless electroceutical device (WED). Scanning electron microscopy demonstrated that the WED disrupted biofilm aggregates on the wound surface and significantly decreased (p<0.05) biofilm burden. Additionally, wounds treated with the WED showed significantly improved wound re-epithelialization (p<0.05) and restored skin barrier function (p<0.05) when compared to the placebo-treated wounds.
“Electrical forces and activity are central to the assembly and integrity of bacterial biofilm. These microbes cannot evade electrodynamic forces as they do pharmacological drugs, making electroceutical intervention a smart choice,” said Dr. Sen. “Pre-clinical studies show that electroceutical wound dressing both prevents and disrupts polymicrobial wound biofilm infection.”
Presence of biofilms in chronic wounds has been well recognized. Because they contribute significantly to complications in wound healing, increased morbidity, decreased quality of life and added healthcare costs, clinicians remain highly motivated to find solutions.
“This latest research further substantiates the antimicrobial and anti-biofilm efficacy of our technology. We are proud to offer clinicians and patients an economical solution to a significant healthcare challenge with our one-of-a-kind electroceutical product,” said Michael Nagel, President and Chief Executive Officer of Vomaris Innovations, Inc.